Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Give Covid-19 vaccine to the young before elderly: Kiran Mazumdar-Shaw

Kiran Mazumdar Shaw is clear about the responsibility of Pharma companies. She says they don't have the luxury to be selective about what data they share with the public, simply because public money is involved. This EXCLUSIVE interview to Govindraj Ethiraj delves into who should get vaccines first - the young or the vulnerable?&nbsp;
- Whether it's possible to shrink the regulatory processes and timelines in vaccine or drug delivery for emergency use?
- Challenges of managing multiple vaccine deliveries with our constrained public health resources
- The need for a Pandemic Preparedness Technology Platform,
- Ongoing public health challenges triggered by the pandemic and our attempts at meeting them.
- How innovation can tackle a public health crisis like Covid19.
Referring to her own experience with Biocon's Itolizumab - a drug that ultimately did not become a part of Covid19 clinical management protocol, she says they got emergency use authorisation because, "We were able to demonstrate safety and showed some amount of efficacy".

platform

Categories